VERA News and Press, Vera Therapeutics Inc.

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adul...

2026-07-09 15:10:32 ET Vera Therapeutics Overview I last covered Vera Therapeutics ( VERA ) in June 2025. This is a newly minted commercial-stage biopharma that markets Trutakna (atacicept) for the treatment of IgAN.... Read the full article on Seeking Alpha For ...

BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. William Turner, current Chief Regulatory Officer of Vera Therapeutics, is planning t...

2026-07-07 19:12:27 ET Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy July 7, 2026 4:30 PM EDT... Read the full article on Seeking Alpha For further details see: Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Appro...

2026-07-07 12:55:35 ET More on Vera Therapeutics Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for Vera Therapeutics Financial information for Vera T...

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN). 1,2 The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self...

2026-07-03 15:00:02 ET More on Delta Air Lines, Pepsico, etc. PepsiCo Moves To Hold As Growth Questions Persist Delta Air Lines Q2 Earnings Preview: Here Are The Real Long-Term Signals Space Exploration Technologies Corp. (SPCX) Discusses Reusable Rocket Innovations ...

2026-06-23 14:50:00 ET After lagging expectations during recent market volatility, the healthcare sector is showing signs of renewed strength. Jacky He, Vice President of Portfolio Research at TD Asset Management, explains what’s driving the sector’s rebound, the next wa...

2026-06-02 18:15:02 ET Farzin Haque from Jefferies issued a price target of $60.00 for VERA on 2026-06-02 19:56:00. The adjusted price target was set to $60.00. At the time of the announcement, VERA was trading at $31.26. The overall price target consensus is at $71.75 w...

2026-06-02 17:15:04 ET Jefferies analyst issues BUY recommendation for VERA on June 2, 2026 07:56PM ET. The previous analyst recommendation was Buy. VERA was trading at $31.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...